- Home
- TRC vs ATXS Comparison
TRC vs ATXS Comparison
Compare TRC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- ATXS
- Stock Information
- Founded
- TRC 1843
- ATXS 2008
- Country
- TRC United States
- ATXS United States
- Employees
- TRC N/A
- ATXS N/A
- Industry
- TRC Real Estate
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- ATXS Health Care
- Exchange
- TRC Nasdaq
- ATXS Nasdaq
- Market Cap
- TRC 485.7M
- ATXS 401.2M
- IPO Year
- TRC N/A
- ATXS 2015
- Fundamental
- Price
- TRC $17.49
- ATXS $6.28
- Analyst Decision
- TRC
- ATXS Buy
- Analyst Count
- TRC 0
- ATXS 6
- Target Price
- TRC N/A
- ATXS $32.00
- AVG Volume (30 Days)
- TRC 114.7K
- ATXS 261.2K
- Earning Date
- TRC 08-07-2025
- ATXS 08-12-2025
- Dividend Yield
- TRC N/A
- ATXS N/A
- EPS Growth
- TRC N/A
- ATXS N/A
- EPS
- TRC N/A
- ATXS N/A
- Revenue
- TRC $45,307,000.00
- ATXS N/A
- Revenue This Year
- TRC N/A
- ATXS N/A
- Revenue Next Year
- TRC N/A
- ATXS N/A
- P/E Ratio
- TRC N/A
- ATXS N/A
- Revenue Growth
- TRC 14.79
- ATXS N/A
- 52 Week Low
- TRC $14.71
- ATXS $3.56
- 52 Week High
- TRC $19.39
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- TRC 48.22
- ATXS 51.20
- Support Level
- TRC $17.17
- ATXS $6.12
- Resistance Level
- TRC $17.76
- ATXS $6.82
- Average True Range (ATR)
- TRC 0.34
- ATXS 0.37
- MACD
- TRC -0.00
- ATXS -0.03
- Stochastic Oscillator
- TRC 61.29
- ATXS 43.52
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.